Novo-Nordisk A/S (NVO)

Price$44.07

Value ScoreB

Growth ScoreB

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-21.75%

Price vs S&P 500 (4W)9.66%

VGM Score61.28

Market Capitalization$203.79B

P/E Ratio (Annual)12.74x

Indicated Dividend Yield (Annual)3.99%

All Metrics

P/CF (Annual)10.96x

Book Value / Share (Quarterly)$7.15

P/TBV (Annual)17.22x

Indicated Dividend (Annual)$1.83

Revenue Growth (3Y)20.43%

Cash Flow / Share (Quarterly)$1.09

Payout Ratio (TTM)54.86%

Price vs S&P 500 (YTD)-19.93%

Gross Margin (TTM)81.85%

Net Profit Margin (TTM)37.20%

EPS (TTM)$4.28

10-Day Avg Trading Volume6.26M

EPS Excl Extra (TTM)$4.28

Revenue Growth (5Y)19.48%

EPS (Annual)$3.60

Dividend / Share (Annual)$1.82

ROI (Annual)31.52%

Gross Margin (Annual)80.98%

Net Profit Margin (5Y Avg)33.85%

Cash / Share (Quarterly)$0.76

P/E Basic Excl Extra (TTM)10.70x

Revenue Growth QoQ (YoY)23.99%

EPS Growth (5Y)20.66%

P/E Normalized (Annual)12.74x

ROA (Last FY)18.87%

Revenue Growth TTM (YoY)8.13%

EBITD / Share (TTM)$5.97

ROE (5Y Avg)67.14%

Operating Margin (TTM)45.30%

Cash Flow / Share (Annual)$1.02

P/B Ratio6.43x

P/B Ratio (Quarterly)3.85x

Net Income / Employee (Annual)$232,562

EV / Revenue (TTM)4.36x

Net Interest Coverage (TTM)149.07x

ROA (TTM)23.27%

EPS Growth QoQ (YoY)67.08%

EV / EBITDA (TTM)8.40x

EPS Incl Extra (Annual)$3.60

Current Ratio (Annual)0.80x

Quick Ratio (Quarterly)0.56x

3-Month Avg Trading Volume7.75M

52-Week Price Return67.26%

EV / Free Cash Flow (Annual)49.33x

P/E Incl Extra (TTM)10.70x

Revenue / Employee (TTM)$744,229

Tangible BV / Share (Quarterly)$3.27

P/S Ratio (Annual)4.22x

Asset Turnover (Annual)0.57x

52-Week High$533.40

Operating Margin (5Y Avg)42.72%

EPS Excl Extra (Annual)$3.60

CapEx CAGR (5Y)32.48%

Tangible BV CAGR (5Y)14.46%

26-Week Price Return-5.82%

Quick Ratio (Annual)0.57x

13-Week Price Return-2.67%

Total Debt / Equity (Annual)0.67x

Current Ratio (Quarterly)0.79x

Enterprise Value$223.35B

Revenue / Share Growth (5Y)20.70%

Asset Turnover (TTM)0.63x

Book Value / Share Growth (5Y)23.06%

Revenue / Employee (Annual)$701,684

Inventory Turnover (Annual)1.30x

Pretax Margin (Annual)42.24%

Cash / Share (Annual)$0.95

3-Month Return Std Dev48.24%

Gross Margin (5Y Avg)83.54%

Net Income / Employee (TTM)$276,888

EBITDA CAGR (5Y)21.59%

EBITDA Interim CAGR (5Y)31.02%

ROE (Last FY)52.79%

Net Interest Coverage (Annual)28.66x

EPS Basic Excl Extra (Annual)$3.60

P/FCF (TTM)19.40x

Receivables Turnover (TTM)4.31x

EV / Free Cash Flow (TTM)46.09x

Total Debt / Equity (Quarterly)0.72x

EPS Incl Extra (TTM)$4.28

Receivables Turnover (Annual)4.33x

ROI (TTM)40.22%

Dividend Growth Rate (5Y)19.05%

P/S Ratio (TTM)3.98x

Pretax Margin (5Y Avg)42.42%

Revenue / Share (Annual)$10.85

Tangible BV / Share (Annual)$2.95

Forward P/E13.47x

Free OCF CAGR (5Y)-0.60%

Price vs S&P 500 (52W)41.90%

P/E Ratio (TTM)10.70x

EPS Growth TTM (YoY)16.73%

Year-to-Date Return-9.93%

5-Day Price Return1.37%

EPS Normalized (Annual)$3.60

ROA (5Y Avg)22.94%

Net Profit Margin (Annual)33.14%

Month-to-Date Return7.60%

Cash Flow / Share (TTM)$2.86

EBITD / Share (Annual)$5.25

EPS Growth (3Y)23.53%

Operating Margin (Annual)41.30%

LT Debt / Equity (Annual)0.61x

P/CF (TTM)11.00x

ROI (5Y Avg)47.01%

P/E Excl Extra (TTM)10.70x

LT Debt / Equity (Quarterly)0.59x

EPS Basic Excl Extra (TTM)$4.28

P/TBV (Quarterly)8.41x

Payout Ratio (Annual)50.53%

P/B Ratio (Annual)7.44x

Dividend / Share (TTM)$1.83

Inventory Turnover (TTM)1.26x

Pretax Margin (TTM)47.49%

Book Value / Share (Annual)$6.83

Price vs S&P 500 (13W)-12.42%

Net Margin Growth (5Y)-0.03%

Dividend Yield (TTM)4.00%

Beta1.85x

P/FCF (Annual)45.01x

Revenue / Share (TTM)$11.50

ROE (TTM)66.36%

52-Week Low$224.25

vGradeB

gGradeB

mGradeC

vgmGradeB

Show chart for

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.59

3.47

3.38

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
NVONovo-Nordisk A/S	B	B	C	$44.07
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64
VRTXVertex Pharmaceuticals Inc	D	B	C	$438.40

About

Novo Nordisk is the global leader in diabetes care, commanding approximately one-third of the branded diabetes treatment market. The Danish company manufactures insulins, GLP-1 therapies, oral antidiabetics, and obesity treatments. Its smaller biopharmaceutical segment, representing less than 10% of revenue, develops protein therapies for hemophilia and related disorders.